JP2011530309A5 - - Google Patents

Download PDF

Info

Publication number
JP2011530309A5
JP2011530309A5 JP2011523001A JP2011523001A JP2011530309A5 JP 2011530309 A5 JP2011530309 A5 JP 2011530309A5 JP 2011523001 A JP2011523001 A JP 2011523001A JP 2011523001 A JP2011523001 A JP 2011523001A JP 2011530309 A5 JP2011530309 A5 JP 2011530309A5
Authority
JP
Japan
Prior art keywords
nucleic acid
mammal
polypeptide
protein
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011523001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011530309A (ja
Filing date
Publication date
Priority claimed from US12/192,015 external-priority patent/US7951377B2/en
Application filed filed Critical
Publication of JP2011530309A publication Critical patent/JP2011530309A/ja
Publication of JP2011530309A5 publication Critical patent/JP2011530309A5/ja
Pending legal-status Critical Current

Links

JP2011523001A 2008-08-14 2009-08-14 多価ワクチン Pending JP2011530309A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/192,015 US7951377B2 (en) 2005-08-23 2008-08-14 Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
US12/192,015 2008-08-14
PCT/US2009/004664 WO2010019262A2 (en) 2008-08-14 2009-08-14 Polyvalent vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014120307A Division JP2014207910A (ja) 2008-08-14 2014-06-11 多価ワクチン

Publications (2)

Publication Number Publication Date
JP2011530309A JP2011530309A (ja) 2011-12-22
JP2011530309A5 true JP2011530309A5 (enExample) 2012-10-04

Family

ID=41669535

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011523001A Pending JP2011530309A (ja) 2008-08-14 2009-08-14 多価ワクチン
JP2014120307A Pending JP2014207910A (ja) 2008-08-14 2014-06-11 多価ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014120307A Pending JP2014207910A (ja) 2008-08-14 2014-06-11 多価ワクチン

Country Status (9)

Country Link
US (6) US7951377B2 (enExample)
EP (2) EP2318430A4 (enExample)
JP (2) JP2011530309A (enExample)
CN (1) CN102177175A (enExample)
AU (1) AU2009282442B2 (enExample)
BR (1) BRPI0917205A2 (enExample)
CA (1) CA2733898C (enExample)
IL (1) IL211184B (enExample)
WO (1) WO2010019262A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951377B2 (en) 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
CA2620874A1 (en) 2005-08-23 2007-03-01 The Regents Of The University Of California Polyvalent vaccine
HRP20181776T1 (hr) 2008-11-18 2019-02-08 Beth Israel Deaconess Medical Center, Inc. Antivirusna cjepiva sa poboljšanom staničnom imunogenosti
US10040826B2 (en) 2011-07-05 2018-08-07 Duke University Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
WO2014093901A1 (en) 2012-12-13 2014-06-19 Baylor Research Institute At Dallas Triheptanoin for the treatment of glucose transporter 1 deficiency
EP3052517B1 (en) * 2013-09-30 2023-07-19 Triad National Security, LLC Mosaic conserved region hiv immunogenic polypeptides
EP3058065B1 (en) * 2013-10-16 2018-05-02 New England Biolabs, Inc. Reverse transcriptase with enhanced properties
US10149902B2 (en) 2014-03-19 2018-12-11 Duke University Swarm immunization with envelopes from CH505
WO2015148602A1 (en) * 2014-03-25 2015-10-01 Duke University Mosaic hiv-1 swquences and uses thereof
CA2944068A1 (en) 2014-03-31 2015-10-08 Duke University Compositions comprising ch848 envelopes and uses thereof
WO2016049522A2 (en) 2014-09-28 2016-03-31 Duke University Compositions comprising ch505 envelopes, and trimers
CA3016327A1 (en) 2016-03-01 2017-09-08 Duke University Compositions comprising hiv envelopes to induce ch235 lineage antibodies
EP3423091A4 (en) 2016-03-03 2019-10-30 Duke University COMPOSITIONS AND METHODS OF INDUCING HIV-1 ANTIBODIES
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
EP3519428A4 (en) 2016-10-03 2020-07-08 Duke University METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS
EP3526236B1 (en) * 2016-10-17 2025-12-10 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
US11814413B2 (en) 2017-05-25 2023-11-14 Duke University Compositions comprising modified HIV envelopes
WO2020072169A1 (en) 2018-10-01 2020-04-09 Duke University Hiv-1 envelope stabilizing mutations
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
WO2021081437A2 (en) 2019-10-23 2021-04-29 Duke University Compositions comprising v2 opt hiv envelopes
KR20230131481A (ko) 2021-01-14 2023-09-13 길리애드 사이언시즈, 인코포레이티드 Hiv 백신 및 이의 사용 방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6139843A (en) 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US6503753B1 (en) 1998-02-13 2003-01-07 Adan Rios Method for the development of an HIV vaccine
US20030180314A1 (en) 1998-07-10 2003-09-25 Degroot Anne Immunogenic, cross-clade, HIV peptides
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US6710173B1 (en) * 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
US7655774B2 (en) * 2000-02-18 2010-02-02 University Of Washington Ancestral and COT viral sequences, proteins and immunogenic compositions
US20040115621A1 (en) 2000-02-18 2004-06-17 Allen Rodrigo Ancestral viruses and vaccines
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
AU2002363436A1 (en) 2001-11-07 2003-05-19 Duke University Polyvalent immunogen of hiv
US7195768B2 (en) 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
EP1609107A4 (en) * 2003-03-28 2006-08-30 Idm Pharma Inc METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS
WO2004085466A2 (en) 2003-03-28 2004-10-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
CA2539068C (en) 2003-09-15 2013-07-23 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Hiv vaccines based on env of multiple clades of hiv
CN1852734B (zh) 2003-09-17 2010-12-01 杜克大学 共有/祖先免疫原
WO2005035555A1 (en) * 2003-10-10 2005-04-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv/siv env chimeras that promote trimerization and maintain targets of neutralizing antibodies
US7951377B2 (en) 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
CA2620874A1 (en) 2005-08-23 2007-03-01 The Regents Of The University Of California Polyvalent vaccine
WO2007047916A2 (en) 2005-10-17 2007-04-26 Novartis Ag Multiclade hiv vaccines
WO2012047267A2 (en) 2010-09-28 2012-04-12 Duke University Polyvalent immunogen

Similar Documents

Publication Publication Date Title
JP2011530309A5 (enExample)
JP2011136997A5 (enExample)
JP2011155981A5 (enExample)
JP2012126742A5 (enExample)
JP2013172734A5 (enExample)
RU2016146198A (ru) Терапевтические dll4-связывающие белки
JP2010227108A5 (enExample)
JP2012095652A5 (enExample)
JP2013539361A5 (enExample)
HUE042053T2 (hu) Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére
JP2015524422A5 (enExample)
JP2014503206A5 (enExample)
FI3581650T3 (fi) IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
WO2007147529A3 (en) Recombinant viral vaccine
WO2006063101A3 (en) Vaccines for the rapid response to pandemic avian influenza
WO2010138263A3 (en) Novel aav 's and uses thereof
MX2013007918A (es) Peptidos inmunogenicos monomericos y multimericos.
JP2011528896A5 (enExample)
WO2011008956A3 (en) Mammalian genes involved in infection
MY170659A (en) Nucleic acid molecules encoding hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
WO2010134939A3 (en) Mammalian genes involved in infection
JP2014525439A5 (enExample)
WO2013052859A3 (en) Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
WO2010039778A3 (en) Mammalian genes involved in infection
EA200901441A1 (ru) Новые молекулы антител и нуклеиновых кислот, связывающиеся с грибным белком теплового шока hsp90